Respiratory Syncytial Virus (RSV) Infections – Pipeline Review, H1 2020

Global Markets Direct’s, ‘Respiratory Syncytial Virus (RSV) Infections – Pipeline Review, H1 2020’, provides an overview of the Respiratory Syncytial Virus (RSV) Infections pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Respiratory Syncytial Virus (RSV) Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Respiratory Syncytial Virus (RSV) Infections and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape of Respiratory Syncytial Virus (RSV) Infections

– The report reviews pipeline therapeutics for Respiratory Syncytial Virus (RSV) Infections by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Respiratory Syncytial Virus (RSV) Infections therapeutics and enlists all their major and minor projects

– The report assesses Respiratory Syncytial Virus (RSV) Infections therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Respiratory Syncytial Virus (RSV) Infections

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Respiratory Syncytial Virus (RSV) Infections

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Respiratory Syncytial Virus (RSV) Infections pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Abhelix LLC

Abivax SA

ADMA Biologics Inc

Advac LLC

Advance Vaccine Laboratories Pty Ltd

Airway Therapeutics LLC

AlloVir Inc

Anima Biotech Inc

Aridis Pharmaceuticals Inc

Ark Biosciences Inc

Artificial Cell Technologies Inc

AstraZeneca Plc

Atea Pharmaceuticals Inc

Bavarian Nordic A/S

Beijing Advaccine Biotechnology Company Ltd

BioComo Inc

BlueWillow Biologics Inc

BravoVax Co Ltd

Calder Biosciences Inc

Changchun Bcht Biotechnology Co Ltd

Cidara Therapeutics Inc

Clover Biopharmaceuticals

Codagenix Inc

Curevac AG

DBV Technologies SA

Enanta Pharmaceuticals Inc

Enyo Pharma SA

F. Hoffmann-La Roche Ltd

Gene Techno Science Co Ltd

Gilead Sciences Inc

GlaxoSmithKline Plc

HanaVax Inc

Heartland Vaccines LLC

Humabs BioMed SA

iBio Inc

Icosavax Inc

IDBiologics Inc

ILiAD Biotechnologies LLC

Immunwork Inc

IMV Inc

Inovio Pharmaceuticals Inc

Johnson & Johnson

Karyopharm Therapeutics Inc

mAbxience SA

Mapp Biopharmaceutical Inc

Meissa Vaccines Inc

Merck & Co Inc

Moderna Inc

Mucommune LLC

Navigen Inc

NeuClone Pty Ltd

Neuracle Science Co Ltd

Novavax Inc

Pfizer Inc

Phoenix Biotechnology Inc

Pneumagen Ltd

Profectus BioSciences Inc

ReViral Ltd

Riboscience LLC

Ridgeback Biotherapeutics LP

Romark Laboratories LC

Sagimet Biosciences

Sanofi

Shandong Danhong Pharmaceutical Co Ltd

Shionogi & Co Ltd

Sigmovir Biosystems Inc

Signia Therapeutics

TechnoVax Inc

Themis Bioscience GmbH

Trimunocor Ltd

Vault Pharma Inc

Viramatix Sdn Bhd

Viravaxx AG

Virometix AG

Visterra Inc

VLP Biotech Inc

Wyvern Pharmaceuticals Inc

X4 Pharmaceuticals Inc

Zhuhai Trinomab Biotechnology Co Ltd

Table of Contents

Table of Contents

Introduction

Respiratory Syncytial Virus (RSV) Infections - Overview

Respiratory Syncytial Virus (RSV) Infections - Therapeutics Development

Respiratory Syncytial Virus (RSV) Infections - Therapeutics Assessment

Respiratory Syncytial Virus (RSV) Infections - Companies Involved in Therapeutics Development

Respiratory Syncytial Virus (RSV) Infections - Drug Profiles

Respiratory Syncytial Virus (RSV) Infections - Dormant Projects

Respiratory Syncytial Virus (RSV) Infections - Discontinued Products

Respiratory Syncytial Virus (RSV) Infections - Product Development Milestones

Appendix

List of Tables

List of Tables

Number of Products under Development for Respiratory Syncytial Virus (RSV) Infections, H1 2020

Number of Products under Development by Companies, H1 2020

Number of Products under Development by Companies, H1 2020 (Contd..1), H1 2020

Number of Products under Development by Companies, H1 2020 (Contd..2), H1 2020

Number of Products under Development by Companies, H1 2020 (Contd..3), H1 2020

Number of Products under Development by Universities/Institutes, H1 2020

Number of Products under Development by Universities/Institutes, H1 2020 (Contd..1), H1 2020

Products under Development by Companies, H1 2020

Products under Development by Companies, H1 2020 (Contd..1), H1 2020

Products under Development by Companies, H1 2020 (Contd..2), H1 2020

Products under Development by Companies, H1 2020 (Contd..3), H1 2020

Products under Development by Companies, H1 2020 (Contd..4), H1 2020

Products under Development by Companies, H1 2020 (Contd..5), H1 2020

Products under Development by Universities/Institutes, H1 2020

Products under Development by Universities/Institutes, H1 2020 (Contd..1), H1 2020

Number of Products by Stage and Target, H1 2020

Number of Products by Stage and Mechanism of Action, H1 2020

Number of Products by Stage and Route of Administration, H1 2020

Number of Products by Stage and Molecule Type, H1 2020

Respiratory Syncytial Virus (RSV) Infections – Pipeline by Abhelix LLC, H1 2020

Respiratory Syncytial Virus (RSV) Infections – Pipeline by Abivax SA, H1 2020

Respiratory Syncytial Virus (RSV) Infections – Pipeline by ADMA Biologics Inc, H1 2020

Respiratory Syncytial Virus (RSV) Infections – Pipeline by Advac LLC, H1 2020

Respiratory Syncytial Virus (RSV) Infections – Pipeline by Advance Vaccine Laboratories Pty Ltd, H1 2020

Respiratory Syncytial Virus (RSV) Infections – Dormant Projects, H1 2020

Respiratory Syncytial Virus (RSV) Infections – Dormant Projects, H1 2020 (Contd..1), H1 2020

Respiratory Syncytial Virus (RSV) Infections – Dormant Projects, H1 2020 (Contd..2), H1 2020

Respiratory Syncytial Virus (RSV) Infections – Dormant Projects, H1 2020 (Contd..3), H1 2020

Respiratory Syncytial Virus (RSV) Infections – Dormant Projects, H1 2020 (Contd..4), H1 2020

Respiratory Syncytial Virus (RSV) Infections – Dormant Projects, H1 2020 (Contd..5), H1 2020

Respiratory Syncytial Virus (RSV) Infections – Discontinued Products, H1 2020

List of Figures

List of Figures

Number of Products under Development for Respiratory Syncytial Virus (RSV) Infections, H1 2020

Number of Products under Development by Companies, H1 2020

Number of Products under Development by Universities/Institutes, H1 2020

Number of Products by Top 10 Targets, H1 2020

Number of Products by Stage and Top 10 Targets, H1 2020

Number of Products by Top 10 Mechanism of Actions, H1 2020

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020

Number of Products by Top 10 Routes of Administration, H1 2020

Number of Products by Stage and Top 10 Routes of Administration, H1 2020

Number of Products by Top 10 Molecule Types, H1 2020

Number of Products by Stage and Top 10 Molecule Types, H1 2020

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports